|

Prevention of Pacemaker Lead Induced Tricuspid regurgitAtion by Transesophageal eCho guidEd Implantation (PLACE)

RECRUITINGN/ASponsored by LMU Klinikum
Actively Recruiting
PhaseN/A
SponsorLMU Klinikum
Started2022-10-01
Est. completion2027-10
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05667519

Summary

This is the first randomized controlled trial comparing transesophageal echocardiography + fluoroscopy guided lead implantation vs. standard lead implantation guided by fluoroscopy only. Patients are randomized 1:1 in the two groups and followed up for up to 3 years.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* indication for right ventricular lead implantation according to current guidelines

Exclusion Criteria:

* preexisting tricuspid regurgitation ≥ grade 2
* other severe heart valve disease
* history of tricuspid valve treatment
* preexisting right ventricular lead
* chronic dialysis
* contraindication for transesophageal echocardiography

Conditions3

Heart DiseasePacemaker ComplicationTricuspid Regurgitation

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.